Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Industry Goes On Offensive Against Prescription Pseudoephedrine Trend

This article was originally published in The Pink Sheet Daily

Executive Summary

Drug firms hope to dissuade states from moving drugs that contain methamphetamine precursors to prescription status by funding electronic systems to track nonprescription sales of the products.

You may also be interested in...



Wyden To Propose Prescription-Only Status For Pseudoephedrine

Legislation drafted by Sen. Ron Wyden would require prescriptions for all products containing the methamphetamine precursor pseudoephedrine

Rite Aid Joins Fragmented Electronic Effort Against “Smurfing”

Some drugstore chains are tracking sales of methamphetamine precursors with their own electronic systems, but Sen. Chuck Grassley says a national approach may be needed to effectively prevent consumers from evading limits on retail purchases of the products

Database Funding Needed To Sell Investigators On Combat Meth Enforcement

Adequate funding for electronic databases to track retail sales of pseudoephedrine products may be needed to convince law enforcement officials in states besieged by manufacturing of methamphetamine that current PSE sales restrictions are sufficient

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS068645

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel